This repository has been archived by the owner on Oct 31, 2023. It is now read-only.
-
Notifications
You must be signed in to change notification settings - Fork 61
/
ie_parsed_clinical_trials.tsv
We can make this file beautiful and searchable if this error is corrected: It looks like row 3 should actually have 9 columns, instead of 6 in line 2.
281 lines (281 loc) · 66 KB
/
ie_parsed_clinical_trials.tsv
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
#nct_id eligibility_type criterion label term ner_score concepts tree_numbers nel_score
NCT04346355 inclusion Real time polymerase chain reaction (PCR) diagnosis of Sars-CoV2 infection word_scores:chronic_disease sars-cov2 infection 0.925 COVID-19 C01.925 1.000
NCT04346355 inclusion Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or pulmonary ultrasound) word_scores:treatment chest ct scan chest x-ray pulmonary ultrasound 0.899
NCT04346355 inclusion Presence of acute respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) between 200 and 300 mm/Hg word_scores:chronic_disease acute respiratory distress syndrome 0.964 Respiratory Distress Syndrome, Adult C08.381.840|C08.618.840 1.000
NCT04346355 inclusion Presence of exaggerated inflammatory response defined by the presence of at least 1 of the following criteria: Serum CRP greater than or equal to 10 mg/dl word_scores:clinical_variable serum crp 0.946
NCT04346355 exclusion Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or word_scores:chronic_disease respiratory distress syndrome 0.982 Respiratory Distress Syndrome, Adult C08.381.840|C08.618.840 1.000
NCT04346355 exclusion Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or word_scores:clinical_variable oxygen / fraction inspired oxygen 0.777
NCT04346355 exclusion Patients in non-invasive ventilation or word_scores:treatment non-invasive ventilation 0.947 Noninvasive Ventilation E02.041.625.591|E02.880.820.657 1.000
NCT04346355 exclusion Severe heart and kidney failure word_scores:chronic_disease severe heart kidney failure 0.924 Heart A07.541 1.000
NCT04346355 exclusion Severe heart and kidney failure word_scores:chronic_disease severe heart kidney failure 0.924 Kidney Failure C12.777.419.780|C13.351.968.419.780 1.000
NCT04346355 exclusion Pregnant or breastfeeding patient word_scores:pregnancy pregnant 1.000 Pregnancy G08.686.784.769 1.000
NCT04346355 exclusion Known hypersensitivity to TCZ or its excipients word_scores:allergy_name tcz 0.991
NCT04346355 exclusion Patient being treated with immuno-depressors or anti-rejection drugs word_scores:treatment immuno-depressors anti-rejection drugs 0.994
NCT04346355 exclusion Known active infections or other clinical conditions that contraindicate TCZ and cannot be treated or resolved according to the physician's judgment word_scores:chronic_disease active infections 0.774
NCT04346355 exclusion glutamate-pyruvate transaminase (GPT) or glutamine oxaloacetic transaminase (GOT) > 5 times the upper limit of the norm word_scores:clinical_variable glutamate-pyruvate transaminase glutamine oxaloacetic transaminase 0.978 Aspartate Aminotransferases D08.811.913.477.700.225 0.765
NCT04346355 exclusion Neutrophils <500 /mmc word_scores:clinical_variable neutrophils 0.996 Neutrophils A11.118.637.415.583|A11.627.340.583|A11.733.689|A15.145.229.637.415.583|A15.382.490.315.583|A15.382.680.689 1.000
NCT04346355 exclusion Platelets <50.000 /mmc word_scores:clinical_variable platelets 0.999 Blood Platelets A11.118.188|A15.145.229.188 1.000
NCT04346355 exclusion Diverticulitis or intestinal perforation word_scores:chronic_disease diverticulitis intestinal perforation 0.996 Diverticulitis C06.405.205.282.500 1.000
NCT04346355 exclusion Diverticulitis or intestinal perforation word_scores:chronic_disease diverticulitis intestinal perforation 0.996 Intestinal Perforation C06.405.469.557 1.000
NCT04346355 exclusion Suspicion of latent tuberculosis word_scores:chronic_disease latent tuberculosis 0.997 Latent Tuberculosis C01.150.252.410.040.552.846.122 1.000
NCT04344951 inclusion For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation word_scores:gender women 0.999 Women M01.975 1.000
NCT04344951 inclusion For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation word_scores:contraception_consent use be willing to use a double contraceptive method 0.957
NCT04344951 inclusion For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation word_scores:pregnancy urine pregnancy test 0.854
NCT04344951 inclusion For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation word_scores:pregnancy pregnancy will 0.886
NCT04344951 inclusion Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively word_scores:chronic_disease upper respiratory lower respiratory tract infection 0.928 Upper Respiratory Tract Infections C01.748|C08.730 1.000
NCT04344951 inclusion Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers word_scores:chronic_disease respiratory secretion 0.714
NCT04344951 exclusion Serum AST values greater than 5 times the upper normal range word_scores:clinical_variable serum ast values 0.969
NCT04344951 exclusion Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study word_scores:pregnancy pregnancy 0.998 Pregnancy G08.686.784.769 1.000
NCT04344951 exclusion Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study word_scores:pregnancy pregnancy test 0.889 Pregnancy Tests E01.370.225.970|E01.370.378.620|E05.200.970 1.000
NCT04344951 exclusion Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study word_scores:pregnancy pregnancy 0.883 Pregnancy G08.686.784.769 1.000
NCT04344444 inclusion Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease word_scores:clinical_variable oxygen saturation 0.925
NCT04344444 inclusion Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease word_scores:clinical_variable oxygen saturation 0.799
NCT04344444 exclusion QTc greater than 450 milliseconds on screening EKG word_scores:clinical_variable qtc 0.981
NCT04344444 exclusion Pregnant or lactating women word_scores:pregnancy pregnant 0.999 Pregnancy G08.686.784.769 1.000
NCT04344444 exclusion Pregnant or lactating women word_scores:gender women 0.997 Women M01.975 1.000
NCT04344444 exclusion Inability to take oral pills or inability to use a feeding tube word_scores:treatment oral pills 0.899
NCT04344444 exclusion use of azithromycin or hydroxychloroquine within 30 days prior to admission word_scores:treatment azithromycin hydroxychloroquine 0.919 Azithromycin D02.540.576.500.992.050 1.000
NCT04344444 exclusion use of azithromycin or hydroxychloroquine within 30 days prior to admission word_scores:treatment azithromycin hydroxychloroquine 0.919 Hydroxychloroquine D03.633.100.810.050.180.350 1.000
NCT04344080 inclusion confirmed COVID-19 disease word_scores:chronic_disease covid-19 disease 0.972 COVID-19 C01.925 1.000
NCT04344080 inclusion refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg word_scores:clinical_variable norepinephrine 0.837 Norepinephrine D02.033.100.291.502|D02.092.063.480|D02.092.211.215.746|D02.092.311.830|D02.455.426.559.389.657.166.175.830 1.000
NCT04344080 inclusion IL6 ≥ 500 ng/l word_scores:clinical_variable il6 0.981 Interleukin-6 D12.644.276.374.465.224|D12.776.467.374.465.202|D23.529.374.465.224 1.000
NCT04344080 inclusion Indication for CRRT or ECMO word_scores:treatment crrt ecmo 0.985 Extracorporeal Membrane Oxygenation E02.880.301|E04.292.451 1.000
NCT04344080 exclusion Liver cirrhosis Child Pugh C word_scores:chronic_disease liver cirrhosis child pugh c 0.725
NCT04344080 exclusion pregnancy or breastfeeding word_scores:pregnancy pregnancy 0.999 Pregnancy G08.686.784.769 1.000
NCT04344080 exclusion participation in another interventional trial word_scores:treatment interventional trial 0.987
NCT04344015 inclusion Prior diagnosis of COVID-19 documented by a laboratory test approved by the FDA word_scores:chronic_disease covid-19 documented 0.951 COVID-19 C01.925 1.000
NCT04344015 inclusion Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies word_scores:pregnancy previously pregnant female 0.923
NCT04344015 inclusion Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies word_scores:gender male donors 0.996
NCT04344015 inclusion Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies word_scores:gender female donors 0.874
NCT04344015 inclusion Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies word_scores:gender donors 0.855 Donors M01.898 1.000
NCT04344015 exclusion Female donors with HLA antibodies (per FDA requirements for convalescent plasma donors) word_scores:gender female donors 0.893
NCT04344015 exclusion Currently pregnant word_scores:pregnancy pregnant 0.949 Pregnancy G08.686.784.769 1.000
NCT04343989 inclusion Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time RT-PCR using nasopharyngeal swab sample, or equivalent test available to be performed by the NYU Langone clinical laboratory). Effort will be made to have the confirmatory test result <72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases word_scores:chronic_disease covid-19 disease 0.773 COVID-19 C01.925 1.000
NCT04343989 inclusion Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease word_scores:chronic_disease respiratory failure manifesting 0.924
NCT04343989 inclusion Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease word_scores:chronic_disease acute respiratory distress syndrome 0.900 Respiratory Distress Syndrome, Adult C08.381.840|C08.618.840 1.000
NCT04343989 inclusion Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease word_scores:clinical_variable spo2 0.783
NCT04343989 inclusion CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease word_scores:clinical_variable crp 0.941
NCT04343989 inclusion CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease word_scores:clinical_variable ratio 0.771
NCT04343989 inclusion CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease word_scores:chronic_disease cardiac disease 0.837 Heart Diseases C14.280 1.000
NCT04343989 inclusion Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as word_scores:gender women 1.000 Women M01.975 1.000
NCT04343989 inclusion Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as word_scores:contraception_consent able to use one highly effective contraceptive method 0.865
NCT04343989 inclusion combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal) word_scores:contraception_consent progestogen containing hormonal contraception combined 0.840
NCT04343989 inclusion combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal) word_scores:contraception_consent estrogen progestogen containing hormonal contraception 0.855 Estrogens D27.505.696.399.472.277 1.000
NCT04343989 inclusion combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal) word_scores:contraception_consent transdermal 0.875
NCT04343989 inclusion progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) word_scores:contraception_consent progestogen-only hormonal contraception associated 0.743
NCT04343989 inclusion progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) word_scores:treatment oral 0.774 Oral Stage F01.752.747.722.626|F02.739.794.793.626 1.000
NCT04343989 inclusion progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) word_scores:treatment injectable implantable 0.744 Contraceptives, Injections, Consent CC01.01.01.04 0.875
NCT04343989 inclusion progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) word_scores:treatment injectable implantable 0.744 Contraceptives, Implant, Consent CC01.03.02 1.000
NCT04343989 inclusion intrauterine device (IUD) word_scores:contraception_consent intrauterine device 0.969 Intrauterine Devices, Consent CC01.03.01 1.000
NCT04343989 inclusion intrauterine hormone-releasing system (IUS) word_scores:treatment intrauterine hormone-releasing system 0.815
NCT04343989 inclusion true abstinence. when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence, such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception word_scores:contraception_consent methods contraception 0.833
NCT04343989 inclusion Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent word_scores:gender men must 0.999
NCT04343989 inclusion Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent word_scores:contraception_consent willing to use a double-barrier contraception from 0.971
NCT04343989 exclusion Known active inflammatory bowel disease word_scores:chronic_disease inflammatory bowel disease 0.995 Inflammatory Bowel Diseases C06.405.205.731|C06.405.469.432 1.000
NCT04343989 exclusion Known active, untreated diverticulitis word_scores:chronic_disease diverticulitis 0.999 Diverticulitis C06.405.205.282.500 1.000
NCT04343989 exclusion Known untreated bacteremia word_scores:chronic_disease bacteremia 0.998 Bacteremia C01.150.252.100|C01.757.100|C23.550.470.790.500.100 1.000
NCT04343989 exclusion Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis) word_scores:pregnancy pregnancy 0.996 Pregnancy G08.686.784.769 1.000
NCT04343989 exclusion Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis) word_scores:pregnancy pregnant 0.949 Pregnancy G08.686.784.769 1.000
NCT04343989 exclusion Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis) word_scores:pregnancy pregnancy however 0.863
NCT04343989 exclusion Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis) word_scores:pregnancy pregnant study 0.782
NCT04343989 exclusion Known hypersensitivity to the clazakizumab word_scores:allergy_name clazakizumab 0.990
NCT04342182 inclusion Patients with PCR confirmed COVID disease word_scores:chronic_disease covid disease 0.909 COVID-19 C01.925 1.000
NCT04342182 inclusion A history of COVID infection that was documented by PCR word_scores:chronic_disease covid infection 0.967 COVID-19 C01.925 1.000
NCT04342182 inclusion Known ABO-Resus(D) blood group word_scores:chronic_disease abo-resus 0.846
NCT04342182 inclusion A negative screening for irregular antibodies word_scores:treatment irregular antibodies 0.841
NCT04342182 inclusion Donors will be restricted to those who had a symptomatic COVID infection defined as documented fever 38.0 or higher C for at least 48 hours word_scores:chronic_disease covid infection 0.863 COVID-19 C01.925 1.000
NCT04342182 inclusion Written informed consent regarding the plasmapheresis procedure word_scores:treatment plasmapheresis procedure 0.869
NCT04342182 exclusion Weight <45kg word_scores:clinical_variable weight 0.997 Weights E05.978 0.750
NCT04342182 exclusion Medical history of heart failure word_scores:chronic_disease heart failure 0.999 Heart Failure C14.280.434 1.000
NCT04342182 exclusion History of transfusion with red blood cells, platelets or plasma word_scores:treatment transfusion 0.796
NCT04342182 exclusion Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor word_scores:gender female person 0.999
NCT04342182 exclusion Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor word_scores:gender female donor 0.980
NCT04341389 inclusion Negative in HIV diagnostic test word_scores:chronic_disease hiv diagnostic 0.954 HIV B04.820.650.589.650.350 1.000
NCT04341389 inclusion Axillary temperature ≤37.0°C word_scores:clinical_variable axillary temperature 0.990
NCT04341389 exclusion Family history of seizure, epilepsy, brain or mental disease word_scores:chronic_disease seizure epilepsy brain mental disease 0.996 Seizures C10.597.742|C23.888.592.742 1.000
NCT04341389 exclusion Family history of seizure, epilepsy, brain or mental disease word_scores:chronic_disease seizure epilepsy brain mental disease 0.996 Epilepsy C10.228.140.490 1.000
NCT04341389 exclusion Family history of seizure, epilepsy, brain or mental disease word_scores:chronic_disease seizure epilepsy brain mental disease 0.996 Brain A08.186.211 1.000
NCT04341389 exclusion Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past word_scores:allergy_name investigational vaccine 0.846
NCT04341389 exclusion Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months word_scores:gender woman 0.999 Women M01.975 1.000
NCT04341389 exclusion Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months word_scores:pregnancy pregnant 0.982 Pregnancy G08.686.784.769 1.000
NCT04341389 exclusion Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months word_scores:pregnancy gonadotropin pregnancy test 0.732
NCT04341389 exclusion Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months word_scores:pregnancy become pregnant 0.928 Pregnancy G08.686.784.769 1.000
NCT04341389 exclusion Any acute fever disease or infections word_scores:chronic_disease acute fever disease infections 0.882 Infections C01 1.000
NCT04341389 exclusion History of SARS word_scores:chronic_disease sars 0.952 Severe Acute Respiratory Syndrome C01.748.730|C01.925.782.600.550.200.750|C08.730.730 1.000
NCT04341389 exclusion Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease word_scores:chronic_disease chronic illness 0.759 Chronic Disease C23.550.291.500 1.000
NCT04341389 exclusion Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease word_scores:chronic_disease asthma diabetes 0.995 Asthma C08.127.108|C08.381.495.108|C08.674.095|C20.543.480.680.095 1.000
NCT04341389 exclusion Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease word_scores:chronic_disease asthma diabetes 0.995 Diabetes Mellitus C18.452.394.750|C19.246 1.000
NCT04341389 exclusion Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease word_scores:chronic_disease thyroid disease 0.998 Thyroid Diseases C19.874 1.000
NCT04341389 exclusion Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc word_scores:chronic_disease cardiovascular diseases 0.976 Cardiovascular Diseases C14 1.000
NCT04341389 exclusion Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc word_scores:chronic_disease arrhythmia conduction block myocardial infarction 0.968 Arrhythmias, Cardiac C14.280.067|C23.550.073 1.000
NCT04341389 exclusion Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc word_scores:chronic_disease arrhythmia conduction block myocardial infarction 0.968 Myocardial Infarction C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750 1.000
NCT04341389 exclusion Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc word_scores:chronic_disease hypertension 0.970 Hypertension C14.907.489 1.000
NCT04341389 exclusion Hereditary angioneurotic edema or acquired angioneurotic edema word_scores:chronic_disease hereditary angioneurotic edema 0.892 Angioedemas, Hereditary C14.907.079.500|C16.320.798.500.500|C17.800.862.945.066.500|C20.543.480.904.066.500|C20.673.795.500.500 1.000
NCT04341389 exclusion Hereditary angioneurotic edema or acquired angioneurotic edema word_scores:chronic_disease angioneurotic edema 0.929 Angioedema C14.907.079|C17.800.862.945.066|C20.543.480.904.066 1.000
NCT04341389 exclusion No spleen or functional spleen word_scores:chronic_disease functional spleen 0.838
NCT04341389 exclusion Platelet disorder or other bleeding disorder may cause injection contraindication word_scores:chronic_disease platelet disorder 0.976 Blood Platelet Disorders C15.378.140 1.000
NCT04341389 exclusion Platelet disorder or other bleeding disorder may cause injection contraindication word_scores:chronic_disease bleeding disorder 0.919 Feeding Disorders F03.400 0.800
NCT04341389 exclusion Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months word_scores:treatment immunodepressant corticosteroids antianaphylaxis treatment cytotoxic treatment 0.969 Adrenal Cortex Hormones D06.472.040 1.000
NCT04341389 exclusion Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months word_scores:treatment immunodepressant corticosteroids antianaphylaxis treatment cytotoxic treatment 0.969 Antibiotics, Cytotoxic D27.505.954.248.106 1.000
NCT04341389 exclusion Prior administration of other research medicines in last 1 month word_scores:treatment medicines 0.790
NCT04341389 exclusion Prior administration of attenuated vaccine in last 1 month word_scores:treatment attenuated vaccine 0.989 Vaccines, Attenuated D20.215.894.811 0.938
NCT04341389 exclusion Prior administration of inactivated vaccine in last 14 days word_scores:treatment inactivated vaccine 0.947 Vaccines, Inactivated D20.215.894.830 0.941
NCT04341389 exclusion Current anti-tuberculosis prophylaxis or therapy word_scores:treatment anti-tuberculosis prophylaxis therapy 0.986 Therapeutics E02 1.000
NCT04341389 exclusion According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent word_scores:chronic_disease psychological 0.765
NCT04340557 inclusion Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92% word_scores:chronic_disease respiratory disease 0.768
NCT04340557 inclusion Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92% word_scores:clinical_variable oxygen saturation level 0.781
NCT04340557 inclusion Systolic blood pressure ≥ 110 mmHg word_scores:clinical_variable systolic blood pressure 0.998
NCT04340557 inclusion Access to an electronic device that is able to access DocuSign® online and email for consenting word_scores:technology_access access to an electronic device able to access docusign® 0.884
NCT04340557 inclusion Able to read/write/speak English or Spanish fluently word_scores:language_fluency able to read / write / speak english spanish fluently 0.986
NCT04340557 inclusion Negative pregnancy test for women of childbearing potential word_scores:pregnancy negative pregnancy test 0.979 Pregnancy Tests E01.370.225.970|E01.370.378.620|E05.200.970 1.000
NCT04340557 inclusion Negative pregnancy test for women of childbearing potential word_scores:gender women 0.998 Women M01.975 1.000
NCT04340557 exclusion Severe allergy to any ARB or ACE-inhibitor, including angioedema word_scores:allergy_name arb ace-inhibitor 0.986
NCT04340557 exclusion Severe allergy to any ARB or ACE-inhibitor, including angioedema word_scores:allergy_name angioedema 0.979 Angioedema C14.907.079|C17.800.862.945.066|C20.543.480.904.066 1.000
NCT04340557 exclusion Home meds include any kind of ACE inhibitor or ARB word_scores:treatment ace inhibitor arb 0.987 Angiotensin-Converting Enzyme Inhibitors D27.505.519.389.745.085 0.909
NCT04340557 exclusion SBP <110 mmHg word_scores:clinical_variable sbp 0.947
NCT04340557 exclusion Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm) word_scores:chronic_disease acute kidney injury 0.874 Acute Kidney Injury C12.777.419.780.050|C13.351.968.419.780.050 1.000
NCT04340557 exclusion Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm) word_scores:treatment treatment 0.705 Therapeutics E02 1.000
NCT04340557 exclusion Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm word_scores:clinical_variable hyperkalemia 0.914 Hyperkalemia C18.452.950.396 1.000
NCT04340557 exclusion Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm word_scores:treatment treatment 0.701 Therapeutics E02 1.000
NCT04340557 exclusion Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm word_scores:clinical_variable creatinine clearance 0.996
NCT04340050 inclusion Prior diagnosis of COVID-19 documented by a laboratory test (confirmed) word_scores:chronic_disease covid-19 documented 0.849 COVID-19 C01.925 1.000
NCT04340050 inclusion Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors word_scores:gender female donors 0.845
NCT04340050 inclusion Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors word_scores:gender donors 0.893 Donors M01.898 1.000
NCT04340050 inclusion Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors word_scores:pregnancy been pregnant previously pregnant female 0.904
NCT04340050 inclusion Must have severe or immediately life-threatening COVID-19 word_scores:chronic_disease life-threatening covid-19 0.724
NCT04340050 inclusion Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours word_scores:chronic_disease dyspnea 0.962 Dyspnea C08.618.326|C23.888.852.371 1.000
NCT04340050 inclusion Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours word_scores:clinical_variable blood oxygen saturation 0.838
NCT04340050 inclusion Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours word_scores:clinical_variable inspired oxygen ratio 0.791
NCT04340050 inclusion Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours word_scores:clinical_variable lung infiltrates 0.760
NCT04340050 inclusion Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy word_scores:chronic_disease respiratory failure septic shock 0.915 Respiratory Failure C08.618.846 1.000
NCT04340050 inclusion Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy word_scores:chronic_disease respiratory failure septic shock 0.915 Shock, Septic C01.757.800|C23.550.470.790.500.800|C23.550.835.900.712 1.000
NCT04340050 inclusion Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy word_scores:chronic_disease multiple organ dysfunction 0.906
NCT04340050 inclusion Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy word_scores:chronic_disease multiple organ dysfunction 0.726
NCT04340050 inclusion Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy word_scores:treatment convalescent plasma therapy 0.772
NCT04340050 exclusion Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period word_scores:gender female 0.999 Women M01.975 1.000
NCT04340050 exclusion Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period word_scores:pregnancy positive pregnancy test 0.913 Pregnancy Tests E01.370.225.970|E01.370.378.620|E05.200.970 1.000
NCT04340050 exclusion Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period word_scores:pregnancy planning to become pregnant 0.937
NCT04340050 exclusion Patients currently enrolled in other drug trials that preclude investigational treatment with anti-SARS-CoV-2 convalescent plasma word_scores:treatment investigational treatment anti-sars-cov-2 convalescent plasma 0.851
NCT04348032 inclusion Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation word_scores:cancer ovarian cancer fallopian tube cancer primary peritoneal cancer confirmed 0.968 Ovary Cancer C04.588.322.455|C13.351.500.056.630.705|C13.351.937.418.685|C19.344.410|C19.391.630.705 1.000
NCT04348032 inclusion Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation word_scores:cancer ovarian cancer fallopian tube cancer primary peritoneal cancer confirmed 0.968 Fallopian Tube Cancer C04.588.945.418.365|C13.351.500.056.390.390|C13.351.937.418.365 1.000
NCT04348032 inclusion Initial platinum-resistant relapse, the recurrence time was less than 6 months after the last chemotherapy word_scores:treatment chemotherapy 0.974 Drug Therapy E02.319 1.000
NCT04348032 inclusion Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically word_scores:chronic_disease ascites 0.880 Ascites C23.550.081 1.000
NCT04348032 inclusion Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically word_scores:cancer malignant pleural effusion 0.704 Pleural Effusion, Malignant C04.588.894.797.640.700|C08.528.652.700|C08.528.694.700|C08.785.640.700 1.000
NCT04348032 inclusion ECOG physical status score 0 or 1 word_scores:clinical_variable ecog physical status score 0.943
NCT04348032 inclusion In the previous treatment, there was no antivascular targeted therapy word_scores:treatment treatment 0.779 Therapeutics E02 1.000
NCT04348032 inclusion In the previous treatment, there was no antivascular targeted therapy word_scores:treatment targeted therapy 0.861
NCT04348032 inclusion Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field word_scores:chronic_disease pleural effusion ascites should 0.866 Pleural Effusion C08.528.652 1.000
NCT04348032 inclusion Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field word_scores:treatment ct magnetic resonance imaging according 0.738
NCT04348032 inclusion Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field word_scores:treatment surgical treatment 0.834
NCT04348032 inclusion Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field word_scores:treatment radiotherapy 0.727 Radiotherapy E02.815 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: neutrophil count ≥ 1.5x109 /L word_scores:clinical_variable neutrophil count 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: platelet count ≥ 100x109 PG L word_scores:clinical_variable platelet count 0.996 Platelet Count E01.370.225.500.195.107.740|E01.370.225.625.107.700|E01.370.225.625.625.625|E05.200.500.195.107.740|E05.200.625.107.700|E05.200.625.625.625|E05.242.195.107.740|G04.140.107.740|G09.188.105.700 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: hemoglobin ≥ 9g/dL (blood transfusion is allowed to achieve or maintain this target) word_scores:clinical_variable hemoglobin 0.995 Hemoglobin E|Hemoglobins D12.776.124.400|D12.776.124.400.463.375|D12.776.422.316.762|D12.776.422.316.762.426.375 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: total bilirubin<1.5 normal limit (ULN) word_scores:clinical_variable bilirubin 0.988 Bilirubin D03.383.129.578.840.249.184|D03.633.400.909.249.184|D04.345.783.249.184|D23.767.193.184 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis word_scores:clinical_variable glutamic oxaloacetic transaminase glutamic pyruvic transaminase 0.992 Aspartate Aminotransferases D08.811.913.477.700.225 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis word_scores:clinical_variable glutamic oxaloacetic transaminase glutamic pyruvic transaminase 0.992 Alanine Transaminase D08.811.913.477.700.100 1.000
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis word_scores:cancer liver metastasis 0.948
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min word_scores:clinical_variable serum creatinine 0.988
NCT04348032 inclusion The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min word_scores:clinical_variable calculated creatinine clearance 0.889
NCT04348032 exclusion Have received more than two chemotherapy regimens in the past word_scores:treatment regimens 0.992
NCT04348032 exclusion other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin) word_scores:cancer malignant tumors have 0.977
NCT04348032 exclusion other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin) word_scores:cancer cervical carcinoma situ skin squamous cell carcinoma 0.984 Cancer of the Uterine Cervix C04.588.945.418.948.850|C13.351.500.852.593.131|C13.351.500.852.762.850|C13.351.937.418.875.850 1.000
NCT04348032 exclusion other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin) word_scores:cancer basal cell carcinoma skin 0.942 Carcinoma, Basal Cell C04.557.470.200.165|C04.557.470.565.165 0.773
NCT04348032 exclusion Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg) word_scores:chronic_disease hypertension 0.966 Hypertension C14.907.489 1.000
NCT04348032 exclusion Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg) word_scores:treatment antihypertensive treatment 0.860 Antihypertensive Agents D27.505.954.411.162 0.929
NCT04348032 exclusion Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg) word_scores:clinical_variable systolic blood pressure 0.914
NCT04348032 exclusion Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg) word_scores:clinical_variable diastolic blood pressure 0.938
NCT04348032 exclusion Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females) word_scores:clinical_variable qtc interval 0.719
NCT04348032 exclusion Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females) word_scores:gender females 0.961 Women M01.975 1.000
NCT04348032 exclusion Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females) word_scores:chronic_disease myocardial ischemia myocardial infarction above 0.908 Myocardial Ischemia C14.280.647|C14.907.585 1.000
NCT04348032 exclusion Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females) word_scores:chronic_disease myocardial ischemia myocardial infarction above 0.908 Myocardial Infarction C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750 0.750
NCT04348032 exclusion According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value word_scores:chronic_disease cardiac insufficiency 0.773
NCT04348032 exclusion According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value word_scores:clinical_variable left ventricular ejection fraction was 0.922
NCT04348032 exclusion Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy word_scores:treatment thrombolytic anticoagulant therapy 0.935 Thrombolytic Therapy E02.319.913 1.000
NCT04348032 exclusion Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy word_scores:treatment thrombolytic anticoagulant therapy 0.935 Anticoagulants D27.505.954.502.119 1.000
NCT04348032 exclusion Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy word_scores:clinical_variable inr 0.823 International Normalized Ratio E01.370.225.625.115.320|E05.200.625.115.320 1.000
NCT04348032 exclusion Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy word_scores:clinical_variable prothrombin time 0.906 Prothrombin Time E01.370.225.625.115.610|E05.200.625.115.610|G09.188.680 1.000
NCT04348032 exclusion Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy word_scores:clinical_variable aptt 0.776
NCT04348032 exclusion There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis word_scores:chronic_disease gastrointestinal bleeding hemorrhagic gastric ulcer 0.937 Gastrointestinal Tract A03.556 1.000
NCT04348032 exclusion Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization word_scores:chronic_disease traumatic injuries 0.771
NCT04348032 exclusion Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization word_scores:chronic_disease ulcers occurred 0.835
NCT04348032 exclusion Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization word_scores:treatment major surgical operations 0.850
NCT04348032 exclusion There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction word_scores:treatment oral drug absorption 0.725
NCT04348032 exclusion There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction word_scores:chronic_disease chronic diarrhea intestinal obstruction 0.887 Intestinal Obstruction C06.405.469.531 1.000
NCT04348032 exclusion Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g word_scores:clinical_variable urine routine indicates urinary protein 0.897
NCT04348032 exclusion Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g word_scores:clinical_variable confirms 24-hour urinary protein 0.787
NCT04348032 exclusion Allergic or heterogeneous reactions to doxorubicin and / or related substances word_scores:allergy_name doxorubicin 0.993 Doxorubicin D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175 1.000
NCT04348032 exclusion The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment word_scores:treatment doxorubicin 0.934 Doxorubicin D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175 1.000
NCT04348032 exclusion The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment word_scores:treatment anthracycline 0.909 Anthracyclines D02.455.426.559.847.562.050|D04.615.562.050|D09.408.051.059 0.909
NCT04348032 exclusion The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment word_scores:treatment doxorubicin liposome injection treatment 0.872
NCT04348032 exclusion Uncontrollable arrhythmias or electrocardiograms abnormalities determined by the lead researcher to be at risk word_scores:chronic_disease arrhythmias electrocardiograms abnormalities determined 0.971 Arrhythmias, Cardiac C14.280.067|C23.550.073 0.875
NCT04348032 exclusion A history of doxorubicin liposome therapy in recent half a year word_scores:treatment doxorubicin liposome therapy 0.989
NCT04348032 exclusion Have previously received local radiotherapy of the pelvis or lower abdomen word_scores:treatment radiotherapy 0.996 Radiotherapy E02.815 1.000
NCT04348006 inclusion Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions) word_scores:cancer multiple myeloma 0.896 Multiple Myeloma C04.557.595.500|C14.907.454.460|C15.378.147.780.650|C15.378.463.515.460|C20.683.515.845|C20.683.780.650 1.000
NCT04348006 inclusion Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions) word_scores:chronic_disease hypercalcemia 0.896 Hypercalcemia C18.452.174.451|C18.452.950.340 1.000
NCT04348006 inclusion Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions) word_scores:chronic_disease renal impairment 0.880 Kidney A05.810.453 1.000
NCT04348006 inclusion Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions) word_scores:chronic_disease anemia 0.946 Anemia C15.378.071 1.000
NCT04348006 exclusion Smoldering MM word_scores:cancer smoldering multiple myeloma 0.975 Smoldering Multiple Myeloma C04.834.794|C15.378.147.542.820|C15.378.147.780.838|C20.683.460.820|C20.683.780.838 1.000
NCT04347252 inclusion Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM word_scores:clinical_variable fasting glucose values 0.969
NCT04347252 inclusion Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM word_scores:clinical_variable a1c 0.934
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:chronic_disease infectious malignant inflammatory conditions unstable angina uncompensated heart failure pulmonary disorders copd asthma malabsorptive gastrointestinal disease 0.904
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:chronic_disease hepatic disease renal insufficiency 0.950
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:chronic_disease anemia 0.922 Anemia C15.378.071 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:chronic_disease hypertension 0.810 Hypertension C14.907.489 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:clinical_variable egfr 0.965
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:clinical_variable hematocrit 0.824 Hematocrit E01.370.225.625.400|E05.200.625.400|G09.188.370.374 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:pregnancy pregnancy 0.772 Pregnancy G08.686.784.769 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:treatment glucocorticoids psychotropics narcotics metoclopramide 0.822 Glucocorticoids D06.472.040.543|D27.505.696.399.472.488 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:treatment glucocorticoids psychotropics narcotics metoclopramide 0.822 Narcotics D27.505.696.277.600|D27.505.696.663.850.014.760|D27.505.954.427.040.550|D27.505.954.427.210.600 1.000
NCT04347252 exclusion Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide) word_scores:treatment glucocorticoids psychotropics narcotics metoclopramide 0.822 Metoclopramide D02.065.277.573|D02.241.223.100.050.500.647|D02.241.223.100.100.510|D02.241.223.100.200.750|D02.241.223.100.300.350.625|D02.241.511.390.350.625|D02.455.426.559.389.127.020.937.647|D02.455.426.559.389.127.085.510|D02.455.426.559.389.127.250.750|D02.455.426.559.389.127.281.350.625|D02.455.426.559.389.657.654.638.625 1.000
NCT04344847 exclusion previous gastric surgery word_scores:treatment gastric surgery 0.998
NCT04344847 exclusion patients with hiatus hernia word_scores:chronic_disease hiatus hernia 0.985 Hernia, Hiatal C23.300.707.500.467 1.000
NCT04344678 inclusion Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study word_scores:treatment psychotropic anti-inflammatory medications 0.899
NCT04344678 exclusion Patients with bipolar I or bipolar II disorder word_scores:chronic_disease bipolar i bipolar ii disorder 0.973 Bipolar Disorder F03.084.500 0.812
NCT04344678 exclusion Patients with personality disorders word_scores:chronic_disease personality disorders 0.999 Personality Disorders F03.675 1.000
NCT04344678 exclusion Patients with eating disorders word_scores:chronic_disease eating disorders 0.999 Eating Disorders F03.400 1.000
NCT04344678 exclusion Patients with concurrent active medical condition word_scores:chronic_disease medical condition 0.934
NCT04344678 exclusion Patients with history of seizures word_scores:chronic_disease seizures 1.000 Seizures C10.597.742|C23.888.592.742 1.000
NCT04344678 exclusion Patients with history of receiving Electroconvulsive therapy (ECT) word_scores:treatment electroconvulsive therapy 0.996 Electroconvulsive Therapy F04.570.200.583|F04.669.224.300 1.000
NCT04344678 exclusion Patients with inflammatory disorders word_scores:chronic_disease inflammatory disorders 1.000
NCT04344678 exclusion Patients with allergy or contraindications to the used medications word_scores:allergy_name medications 0.821 Pharmaceutical Preparations D26 0.875
NCT04344678 exclusion Patients with finally pregnant or lactating females word_scores:pregnancy finally pregnant 0.907
NCT04344678 exclusion Patients with finally pregnant or lactating females word_scores:gender females 0.999 Women M01.975 1.000
NCT04344678 exclusion Cardiovascular disorders word_scores:chronic_disease cardiovascular disorders 1.000
NCT04344678 exclusion Severe renal impairment: creatinine clearance of ≤ 25 ml/min word_scores:chronic_disease severe renal impairment 0.875 Kidney A05.810.453 1.000
NCT04344678 exclusion Severe renal impairment: creatinine clearance of ≤ 25 ml/min word_scores:clinical_variable creatinine clearance 0.988
NCT04344678 exclusion Moderate or severe hepatic impairment word_scores:chronic_disease hepatic impairment 0.991 Hepatica B01.650.940.800.575.912.250.836.750 0.800
NCT04344470 inclusion Able to give informed consent word_scores:contraception_consent give informed consent 0.725
NCT04344470 inclusion Fluent in English word_scores:language_fluency fluent english 0.998 Language Fluency, English LF01.01 0.769
NCT04344470 exclusion Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman word_scores:gender man 0.906 Humans|Men B01.050.150.900.649.313.988.400.112.400.400|M01.390 1.000
NCT04344470 exclusion Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman word_scores:gender woman 0.991 Women M01.975 1.000
NCT04344470 exclusion Abnormal findings on neurological examination word_scores:treatment neurological examination 0.911 Neurologic Examination E01.370.376.550|E01.370.600.550 1.000
NCT04344470 exclusion History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures word_scores:cancer brain tumor 0.944 Brain Neoplasms C04.588.614.250.195|C10.228.140.211|C10.551.240.250 1.000
NCT04344470 exclusion History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures word_scores:chronic_disease stroke head trauma 0.903 Stroke C10.228.140.300.775|C14.907.253.855 1.000
NCT04344470 exclusion History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures word_scores:chronic_disease stroke head trauma 0.903 Craniocerebral Trauma C10.900.300|C26.915.300 1.000
NCT04344470 exclusion History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures word_scores:chronic_disease epilepsy 0.939 Epilepsy C10.228.140.490 1.000
NCT04344470 exclusion History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures word_scores:chronic_disease seizures 0.983 Seizures C10.597.742|C23.888.592.742 1.000
NCT04344470 exclusion Current episode of major depression or any major psychiatric illness word_scores:chronic_disease major depression 0.891
NCT04344470 exclusion Current episode of major depression or any major psychiatric illness word_scores:chronic_disease psychiatric illness 0.991 Mental Disorders F03 1.000
NCT04343391 inclusion Emotional Disorder word_scores:chronic_disease emotional disorder 0.999
NCT04343391 exclusion Severe mental disorder word_scores:chronic_disease severe mental disorder 0.867 Mental Disorder 1.000
NCT04343391 exclusion Severe depression word_scores:chronic_disease severe depression 0.845 Depression F01.145.126.350 1.000
NCT04343014 inclusion ASA graded I~II class word_scores:clinical_variable asa graded i~ii class 0.915
NCT04343014 inclusion scheduled for elective surgery requiring orotracheal intubation word_scores:treatment elective surgery requiring orotracheal intubation 0.899
NCT04343014 exclusion with organ transplant operations word_scores:treatment organ transplant operations 0.995
NCT04343014 exclusion with thoracic and cardiac vascular surgery word_scores:treatment thoracic cardiac vascular surgery 0.984 Thoracica B01.050.500.131.365.880 0.833
NCT04343014 exclusion with severe cadiac or pulmonary disease word_scores:chronic_disease cadiac pulmonary disease 0.976 Lung Diseases C08.381 1.000
NCT04342793 inclusion Men or women ages 19 and over, under 75 years of age word_scores:gender men women ages 0.900 Men|Multiple Endocrine Neoplasia Type 2a|Multiple Endocrine Neoplasia Type 2b C04.588.322.400.505|C04.588.322.400.510|C04.651.600.505|C04.651.600.510|C04.700.630.505|C04.700.630.510|C16.320.700.630.505|C16.320.700.630.510|C19.344.400.505|C19.344.400.510|M01.390 1.000
NCT04342793 inclusion Patients diagnosed with NAFLD on abdominal ultrasonography and MRI word_scores:chronic_disease nafld 0.787 Non-alcoholic Fatty Liver Disease C06.552.241.519 1.000
NCT04342793 inclusion Patients diagnosed with NAFLD on abdominal ultrasonography and MRI word_scores:treatment abdominal ultrasonography magnetic resonance imaging 0.836 Magnetic Resonance Imaging E01.370.350.825.500 1.000
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:chronic_disease chronic liver disease 0.890
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:chronic_disease hemochromatosis 0.958 Hemochromatosis C16.320.565.618.337|C18.452.565.500.480|C18.452.648.618.337 1.000
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:chronic_disease autoimmune liver disease viral hepatitis a b alcoholic liver disease 0.925 Hepatitis, Viral, Human C01.925.440|C06.552.380.705 0.857
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:chronic_disease autoimmune liver disease viral hepatitis a b alcoholic liver disease 0.925 Hepatitis B C01.925.256.430.400|C01.925.440.435|C06.552.380.705.437 1.000
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:chronic_disease autoimmune liver disease viral hepatitis a b alcoholic liver disease 0.925 Liver Diseases, Alcoholic C06.552.645|C25.775.100.087.645 1.000
NCT04342793 exclusion Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease word_scores:cancer liver cancer 0.742 Cancer of Liver|Carcinoma, Hepatocellular C04.557.470.200.025.255|C04.588.274.623|C04.588.274.623.160|C06.301.623|C06.301.623.160|C06.552.697|C06.552.697.160 1.000
NCT04342793 exclusion Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening word_scores:chronic_disease diabetes mellitus 0.983 Diabetes Mellitus C18.452.394.750|C19.246 1.000
NCT04342793 exclusion Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening word_scores:clinical_variable hba1c 0.844
NCT04342793 exclusion Patients who are allergic or hypersensitive to the drug or its constituents word_scores:allergy_name drug 0.817 Drug Therapy|Pharmaceutical Preparations D26|E02.319 1.000
NCT04342793 exclusion Pregnant or lactating women word_scores:pregnancy pregnant 0.999 Pregnancy G08.686.784.769 1.000
NCT04342793 exclusion Pregnant or lactating women word_scores:gender women 0.997 Women M01.975 1.000